Overview

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Status:
Terminated

Trial end date:
2019-11-15

Target enrollment:

Participant gender:

Summary

This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).

Phase:

Phase 3

Details

Lead Sponsor:

GlycoMimetics Incorporated
Pfizer